The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Efficacy Results of ARIEL2 Trial in Ovarian Cancer

Elizabeth Swisher, MD
Published Online:7:11 PM, Wed April 19, 2017

Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the results of the ARIEL2 trial in patients in patients with relapsed, platinum-sensitive, high-grade ovarian carcinoma with a germline or somatic BRCA mutation.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.